CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: campestanol
Accession: CHEBI:36799
browse the term
Definition: A 3beta-sterol that has formula C28H50O.
Synonyms: exact_synonym: 5alpha-campestan-3beta-ol
related_synonym: (24R)-5alpha-ergostan-3beta-ol; 5alpha-Campestanol; Formula=C28H50O; InChI=1S/C28H50O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h18-26,29H,7-17H2,1-6H3/t19-,20-,21+,22+,23+,24-,25+,26+,27+,28-/m1/s1; InChIKey=ARYTXMNEANMLMU-ATEDBJNTSA-N; SMILES=[H][C@@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@]([H])(CC[C@@]34[H])[C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC[C@H](O)C2
alt_id: CHEBI:20641; CHEBI:22992
xref: Beilstein:3209563; CAS:474-60-2; KEGG:C15787; KNApSAcK:C00007516; LIPID_MAPS_instance:LMST01030103
G
BCL2
BCL2 apoptosis regulator
decreases expression
EXP
6-oxocampestanol results in decreased expression of BCL2 protein
CTD
PMID:32001316
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
G
BCL2L1
BCL2 like 1
affects expression
EXP
6-oxocampestanol affects the expression of BCL2L1 protein
CTD
PMID:32001316
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
G
BID
BH3 interacting domain death agonist
affects expression
EXP
6-oxocampestanol affects the expression of BID protein
CTD
PMID:32001316
NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
G
CCNB1
cyclin B1
decreases expression
EXP
6-oxocampestanol results in decreased expression of CCNB1 protein
CTD
PMID:32001316
NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245
G
CDKN1A
cyclin dependent kinase inhibitor 1A
increases expression
EXP
6-oxocampestanol results in increased expression of CDKN1A protein
CTD
PMID:32001316
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
G
ESR1
estrogen receptor 1
increases expression
EXP
6-oxocampestanol results in increased expression of ESR1 protein
CTD
PMID:32001316
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
G
ESR2
estrogen receptor 2
affects localization
EXP
6-oxocampestanol affects the localization of ESR2 protein
CTD
PMID:32001316
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
G
PGR
progesterone receptor
affects localization
EXP
6-oxocampestanol affects the localization of PGR protein
CTD
PMID:32001316
NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813
G
RB1
RB transcriptional corepressor 1
multiple interactions
EXP
6-oxocampestanol results in increased expression of and results in increased phosphorylation of RB1 protein
CTD
PMID:32001316
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
G
TP53
tumor protein p53
increases expression
EXP
6-oxocampestanol results in increased expression of TP53 protein
CTD
PMID:32001316
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all